The Basel-based multinational, which supplies the pharma industry, expects the CHF500 million ($522 million) facility to be ready in 2026.
The site in Stein, northern Switzerland, will be dedicated to the specialised tasks of filling vials with vaccine and finishing the packaging for distribution (known as fill and finish in the industry). It is a process that is often outsourced in the pharma sector and known to cause bottlenecks in the availability of new vaccines.
“Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle,” said CEO Pierre-Alain Ruffieux on Friday.
The new facility will be more energy efficient and have a photovoltaic roof. It will be built on the same campus as Lonza’s clinical drug product facility in Stein. The company also manufactures drugs in Basel and Visp, as well as in Guangzhou, China.
Deeply Read
More
Science
Switzerland says it can’t afford to take part in Copernicus programme
Swiss summit divides: neutrality under fire amid Ukraine conference
This content was published on
Leading figures in the Swiss Peoples' Party have argued Switzerland should not have hosted this weekend's summit without Russia.
This content was published on
Art dealers, collectors, and gallery owners from around the world wrapped up several multi-million-dollar deals at Art Basel.
Zelensky wants to ‘make history’ at Swiss peace summit
This content was published on
While Swiss President Viola Amherd spoke of modest objectives at the two-day Summit on Peace in Ukraine, her Ukrainian counterpart Volodymyr Zelensky was more proactive, saying he wanted to make history.
US announces $1.5 billion aid for Ukraine at Swiss peace summit
This content was published on
US Vice President Kamala Harris has announced more than $1.5 billion in aid in part for Ukraine’s energy sector and its humanitarian situation.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pandemic reveals Switzerland’s weak spot in securing foreign talent
This content was published on
Switzerland is increasingly being challenged as a business location because of immigration restrictions. Could the pandemic be a turning point?
Lonza to double production of Covid-19 vaccine at Swiss plant
This content was published on
The Swiss firm will add three more production lines to its plant as part of a larger effort to boost Moderna’s global supply of vaccine doses.
Covid vaccines: how to end the wait for billions of people
This content was published on
A waiver on intellectual property rights could be the key to getting more Covid drugs and vaccines to the developing world. But it's controversial.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.